| Targeting huntingtin expression in patients with Huntington’s disease SJ Tabrizi, BR Leavitt, GB Landwehrmeyer, EJ Wild, C Saft, RA Barker, ... New England Journal of Medicine 380 (24), 2307-2316, 2019 | 675 | 2019 |
| Topography of cerebral atrophy in early Huntington’s disease: a voxel based morphometric MRI study J Kassubek, FD Juengling, T Kioschies, K Henkel, J Karitzky, B Kramer, ... Journal of Neurology, Neurosurgery & Psychiatry 75 (2), 213-220, 2004 | 328 | 2004 |
| Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study DJH Moss, AF Pardiñas, D Langbehn, K Lo, BR Leavitt, R Roos, A Durr, ... The Lancet Neurology 16 (9), 701-711, 2017 | 312 | 2017 |
| Response inhibition subprocesses and dopaminergic pathways: basal ganglia disease effects C Beste, R Willemssen, C Saft, M Falkenstein Neuropsychologia 48 (2), 366-373, 2010 | 240 | 2010 |
| Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease C Saft, J Zange, J Andrich, K Müller, K Lindenberg, B Landwehrmeyer, ... Movement disorders: official journal of the Movement Disorder Society 20 (6 …, 2005 | 226 | 2005 |
| Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial JG de Yebenes, B Landwehrmeyer, F Squitieri, R Reilmann, A Rosser, ... The Lancet Neurology 10 (12), 1049-1057, 2011 | 197 | 2011 |
| Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease G Ellrichmann, E Petrasch-Parwez, DH Lee, C Reick, L Arning, C Saft, ... PloS one 6 (1), e16172, 2011 | 195 | 2011 |
| Treating the whole body in Huntington's disease JB Carroll, GP Bates, J Steffan, C Saft, SJ Tabrizi The Lancet Neurology 14 (11), 1135-1142, 2015 | 182 | 2015 |
| The role of the immune system in Huntington’s disease G Ellrichmann, C Reick, C Saft, RA Linker Journal of Immunology Research 2013 (1), 541259, 2013 | 169 | 2013 |
| An exploratory double‐blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with H untington's disease SD Süssmuth, S Haider, GB Landwehrmeyer, R Farmer, C Frost, ... British journal of clinical pharmacology 79 (3), 465-476, 2015 | 165 | 2015 |
| PGC-1alphaas modifier of onset age in Huntington disease E Taherzadeh-Fard, C Saft, J Andrich, S Wieczorek, L Arning Molecular neurodegeneration 4, 1-4, 2009 | 136 | 2009 |
| PGC-1alpha downstream transcription factors NRF-1 and TFAM are genetic modifiers of Huntington disease E Taherzadeh-Fard, C Saft, DA Akkad, S Wieczorek, A Haghikia, A Chan, ... Molecular neurodegeneration 6, 1-8, 2011 | 134 | 2011 |
| Autonomic nervous system function in Huntington's disease J Andrich, T Schmitz, C Saft, T Postert, P Kraus, JT Epplen, H Przuntek, ... Journal of Neurology, Neurosurgery & Psychiatry 72 (6), 726-731, 2002 | 134 | 2002 |
| NR2A and NR2B receptor gene variations modify age at onset in Huntington disease L Arning, PH Kraus, S Valentin, C Saft, J Andrich, JT Epplen Neurogenetics 6, 25-28, 2005 | 125 | 2005 |
| Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation F Squitieri, M Cannella, G Sgarbi, V Maglione, A Falleni, P Lenzi, ... Mechanisms of ageing and development 127 (2), 217-220, 2006 | 123 | 2006 |
| Response inhibition in Huntington's disease—a study using ERPs and sLORETA C Beste, C Saft, J Andrich, R Gold, M Falkenstein Neuropsychologia 46 (5), 1290-1297, 2008 | 121 | 2008 |
| Mechanisms mediating parallel action monitoring in fronto-striatal circuits C Beste, V Ness, C Lukas, R Hoffmann, S Stüwe, M Falkenstein, C Saft Neuroimage 62 (1), 137-146, 2012 | 106 | 2012 |
| Patterns of CAG repeat instability in the central nervous system and periphery in Huntington’s disease and in spinocerebellar ataxia type 1 R Mouro Pinto, L Arning, JV Giordano, P Razghandi, MA Andrew, T Gillis, ... Human molecular genetics 29 (15), 2551-2567, 2020 | 102 | 2020 |
| Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study R Reilmann, A McGarry, ID Grachev, JM Savola, B Borowsky, E Eyal, ... The Lancet Neurology 18 (2), 165-176, 2019 | 99 | 2019 |
| Chorein‐sensitive polymerization of cortical actin and suicidal cell death in chorea‐acanthocytosis M Föller, A Hermann, S Gu, I Alesutan, SM Qadri, O Borst, EM Schmidt, ... The FASEB Journal 26 (4), 1526-1534, 2012 | 92 | 2012 |
